A01147
antibody from Boster Biological Technology
Targeting: ANGPTL4
ARP4, FIAF, HFARP, NL2, PGAR, pp1158
Antibody data
- Antibody Data
- Antigen structure
- References [2]
- Comments [0]
- Validations [0]
Submit
Validation data
Reference
Comment
Report error
- Product number
- A01147 - Provider product page
- Provider
- Boster Biological Technology
- Product name
- Anti-Angiopoietin-like 4?/ANGPTL4 Antibody Picoband™
- Antibody type
- Polyclonal
- Description
- Polyclonal antibody for ANGIOPOIETIN LIKE 4/ANGPTL4 detection. Host: Rabbit.Size: 100μg/vial. Tested applications: ELISA. Reactive species: Human. ANGIOPOIETIN LIKE 4/ANGPTL4 information: Molecular Weight: 45214 MW; Subcellular Localization: Secreted . Secreted, extracellular space, extracellular matrix . The unprocessed form interacts with the extracellular matrix. This may constitute a dynamic reservoir, a regulatory mechanism of the bioavailability of ANGPTL4 (By similarity); Tissue Specificity: Expressed at high levels in the placenta, heart, liver, muscle, pancreas and lung but expressed poorly in the brain and kidney.
- Reactivity
- Human
- Host
- Rabbit
- Vial size
- 100μg/vial
- Concentration
- Add 0.2ml of distilled water will yield a concentration of 500ug/ml.
- Storage
- At -20°C for one year. After reconstitution, at 4°C for one month. It can also be aliquoted and stored frozen at -20°C for a longer time. Avoid repeated freezing and thawing.
- Handling
- Add 0.2ml of distilled water will yield a concentration of 500ug/ml.
Submitted references Angiopoietin-Related Protein 4-Transcript 3 Increases the Proliferation, Invasion, and Migration of Hepatocellular Carcinoma Cells and Inhibits Apoptosis.
ANGPTL4 overexpression is associated with progression and poor prognosis in breast cancer.
Bai Y, Cui G, Sun X, Wei M, Liu Y, Guo J, Yang Y
DNA and cell biology 2024 Apr;43(4):175-184
DNA and cell biology 2024 Apr;43(4):175-184
ANGPTL4 overexpression is associated with progression and poor prognosis in breast cancer.
Zhao J, Liu J, Wu N, Zhang H, Zhang S, Li L, Wang M
Oncology letters 2020 Sep;20(3):2499-2505
Oncology letters 2020 Sep;20(3):2499-2505
No comments: Submit comment
No validations: Submit validation data